Shanghai, China, November 18, 2024 – Asieris Pharmaceuticals (Stock Code: 688176.SH), a leading global biopharmaceutical company dedicated to advancing innovative therapies for genitourinary tumors and women health with significant unmet medical needs, announced the appointment of Ms. Joanna Zhang as Chief Medical Officer. Ms. Zhang will report directly to Dr. Kevin Pan, Founder, Chairman and CEO of Asieris Pharmaceuticals.
Ms. Joanna Zhang, Chief Medical Officer, Asieris Pharmaceuticals
With over 25 years of experience in the pharmaceutical industry, Joanna has held senior management positions in clinical research, medical affairs, and regulatory affairs at renowned domestic and international pharmaceutical companies such as Hengrui Medicine, Sanofi Pasteur, and Takeda Pharmaceuticals. At Hengrui Medicine, she served as Deputy General Manager and Head of the Central Medical Department, where she led a team of nearly 600 medical affairs professionals and oversaw 167 research projects. During her tenure at Takeda Pharmaceuticals, she was the Head of Medical Affairs for the North Asia region and Vice President of Global Medical Affairs, where she formulated and implemented clinical development plans for new products and accelerating the development and launch of new products.
Prior to entering the industry, Joanna gained 10 years of hands-on clinical experience as a physician, specializing in virology, immunology, disease control, and clinical research. She has published over ten academic papers both domestically and internationally. Joanna has also been a core member of the Medical Group of the Research-based Pharmaceutical Manufacturers Association of China (RDPAC) ,a member of the Chinese Medical Affairs Expert Group, and an Executive Committee Member of the Biological Products Branch of the Chinese Preventive Medicine Association.
Dr. Kevin Pan stated, “We are very pleased to welcome Joanna to Asieris. Her extensive experience in medical affairs, strong medical background, and exceptional project leadership skills are essential for the rapid development of Asieris. We believe that Joanna’s addition will significantly enhance our company’s medical affairs capabilities domestically and expedite the commercialization of innovative products to benefit patients sooner.”
Joanna expressed, “Asieris Pharmaceuticals is a rapidly growing global innovative pharmaceutical company, and I am honored to join the team. With its top-tier medical professionals and a differentiated innovative product pipeline, I am confident in the company’s future development. I look forward to leveraging my expertise and experience in this new journey, collaborating with the team to drive the company’s medical strategy forward and accelerate the delivery of innovative therapies to more patients.”
Joanna holds a Bachelor of Medicine degree from Tianjin Medical University, a Bachelor of Arts degree from Tianjin Normal University. She has undergone study and exchange programs at Cambridge College London in the UK and obtained an EMBA degree from Guanghua School of Management, Peking University.
About Asieris
Founded in March 2010, Asieris Pharmaceuticals (688176.SH) is a global biopharma company specializing in discovering, developing, and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases. We strive to improve human health and help people live more dignified lives. We aim to become a global pharma leader that integrates R&D, manufacturing, and commercialization in our areas of focus, as we provide best-in-class integrated diagnosis and treatment solutions for patients in China and worldwide.
The company has been developing its proprietary R&D platform and core technologies, exploring new mechanisms of action, and efficiently screening and evaluating drug candidates. With a well-established in-house R&D system and expertise in global drug development, Asieris is committed to launching first-in-class drugs and other innovative products to address huge unmet needs in its areas of focus.
Asieris is also enhancing its pipeline for genitourinary diseases via proprietary R&D and strategic partnerships, while closely following cutting-edge technologies and therapeutics. The company strives to discover and identify unmet clinical needs, and adopts a forward-looking approach to product planning and life-cycle management. We aim to establish an outstanding portfolio that covers diagnosis and treatment in a bid to benefit more patients in China and globally. Visit us at asieris.com
